
New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes.

New research reveals that early discontinuation of adjuvant immunotherapy for melanoma does not lead to worse outcomes.

In a recent study, authors argue that psychosocial impacts should be at the forefront of the discussion in acne scarring, noting that psychopharmacological management may be necessary in instances of severe psychiatric comorbidities.

For the past 20 to 25 years, data has shown that half of patients prescribed long-term medications do not take them as prescribed.